Please login to the form below

Not currently logged in
Email:
Password:

Nabriva Therapeutics adds Will Sargent to team

Join as VP of commercial strategy and investor relations
Will Sargent Nabriva Therapeutics

Nabriva Therapeutics has appointed Will Sargent in the newly created position of vice president of commercial strategy and investor relations.

Sargent has over twenty years of experience in the biopharmaceutical industry, including multiple product and line extension launches. His most recent position was as VP of the orthopaedic business unit at Auxilium Pharmaceuticals.

Nabriva is currently moving rapidly to advance its lead product, lefamulin, into phase III clinical studies which are expected to begin enrolling in 2015 and 2016.

He said: “I am excited to join this talented and dedicated team focused on advancing a novel, targeted antibiotic therapy that can impact patients' lives by addressing an unmet medical need.

“I look forward to applying my experience toward the successful development and implementation of the lefamulin commercial strategy and expansion of corporate communications.”

Dr Colin Broom, CEO of Nabriva, added: “Will's strategic focus, experience and breadth of knowledge will help us plan and execute toward our commercial path goals.”

14th October 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics